Phase IIa to explore the effectiveness of DMT in combination with psychotherapy for the potential treatment of Major Depressive Disorder Program remains on track for topline results in H1 2022 LONDON, Oct. 19, 2021 (GLOBE NEWSWIRE) — Small Pharma Inc. (TSXV: DMT) (the “ Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies, today announced that the…


Previous articlePT267 – Rebecca Kronman, LCSW – Psychedelics, Pregnancy, and Parenthood
Next articlePharmaTher Engages Alcami for Clinical and Commercial Manufacturing of Novel Ketamine Products